553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition

• Peter Joyce,
• Martin Quibell,
• Jason Shiers,
• Carmen Tong,
• Kristopher Clark,
• Nicola Ternette,
• Andrew Leishman,
• Kate Anderton,
• Jessica Sette,
• Wayne Paes

Affiliations

Peter Joyce

1Grey Wolf Therapeutics Ltd, Oxford, UK

Martin Quibell

1Grey Wolf Therapeutics Ltd, Oxford, UK

Jason Shiers

2Sygnature Discovery, Nottingham, UK

Carmen Tong

2Sygnature Discovery, Nottingham, UK

Kristopher Clark

Internal Medicine Residency Program, Boston Medical Center, Boston, Massachusetts, USA

Nicola Ternette

6University of Oxford, Oxford, UK

Andrew Leishman

1Grey Wolf Therapeutics Ltd, Oxford, UK

Kate Anderton

2Grey Wolf Therapeutics, Oxford, UK

Jessica Sette

2Grey Wolf Therapeutics, Oxford, UK

Wayne Paes

4University of Oxford, Oxford, UK